BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$8.13 USD
-0.15 (-1.81%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $8.14 +0.01 (0.12%) 6:36 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.13 USD
-0.15 (-1.81%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $8.14 +0.01 (0.12%) 6:36 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Zacks News
Strength Seen in BioCryst (BCRX): Can Its 21% Jump Turn into More Strength?
by Zacks Equity Research
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -38.46% and 48.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q1 Earnings Expected to Decline
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -36.00% and -72.72%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for BioCryst (BCRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo
by Zacks Equity Research
BioCryst (BCRX) gets approval in Japan for oral, once-daily Orladeyo 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.
Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.
BioCryst (BCRX) Provides Updates on Galidesivir, Shares Fall
by Zacks Equity Research
BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19).
The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals
5 Healthcare Stocks That Fared Well in 2020 Amid the Pandemic
by Zacks Equity Research
We take a sneak peek into five healthcare stocks that have performed well in 2020 driven by their improved capabilities to cope with the COVID-19 crisis.
Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News
by Zacks Equity Research
Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.
BioCryst (BCRX) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
BioCryst (BCRX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
BioCryst (BCRX) Wins FDA Approval for HAE Drug Orladeyo
by Zacks Equity Research
BioCryst (BCRX) obtains FDA approval for berotralstat for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients.
Are Options Traders Betting on a Big Move in BioCryst Pharmaceuticals (BCRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -4.00% and 41.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
Encompass Health's (EHC) Expansion Plans Continue in Florida
by Zacks Equity Research
Encompass Health (EHC) continues to expand in Florida via hospitals in order to offer improved health services in the state.
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of 14.29% and -9.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Encompass Health Continues to Strengthen Presence in Florida
by Zacks Equity Research
Encompass Health (EHC) intends to offer improved health outcomes through plans to construct a new hospital in Florida, where it already boasts of a strong base.
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BCRX) Outperforming Other Medical Stocks This Year?
Implied Volatility Surging for BioCryst (BCRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.